Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) FCF Margin (2023 - 2025)

Historic FCF Margin for NewAmsterdam Pharma (NAMS) over the last 3 years, with Q3 2025 value amounting to 9428.45%.

  • NewAmsterdam Pharma's FCF Margin fell 93852400.0% to 9428.45% in Q3 2025 from the same period last year, while for Sep 2025 it was 410.12%, marking a year-over-year increase of 507600.0%. This contributed to the annual value of 349.49% for FY2024, which is 6529400.0% up from last year.
  • As of Q3 2025, NewAmsterdam Pharma's FCF Margin stood at 9428.45%, which was down 93852400.0% from 197.23% recorded in Q2 2025.
  • NewAmsterdam Pharma's 5-year FCF Margin high stood at 43.2% for Q3 2024, and its period low was 9428.45% during Q3 2025.
  • In the last 3 years, NewAmsterdam Pharma's FCF Margin had a median value of 1411.35% in 2023 and averaged 2357.61%.
  • Its FCF Margin has fluctuated over the past 5 years, first soared by 38256900bps in 2024, then crashed by -93852400bps in 2025.
  • Quarter analysis of 3 years shows NewAmsterdam Pharma's FCF Margin stood at 4119.18% in 2023, then skyrocketed by 93bps to 293.49% in 2024, then plummeted by -3113bps to 9428.45% in 2025.
  • Its last three reported values are 9428.45% in Q3 2025, 197.23% for Q2 2025, and 1225.12% during Q1 2025.